Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care.

OBJECTIVE To develop clinical practice guidelines for a simplified approach to primary prevention of cardiovascular disease (CVD), concentrating on CVD risk estimation and lipid management for primary care clinicians and their teams; we sought increased contribution from primary care professionals with little or no conflict of interest and focused on the highest level of evidence available. METHODS Nine health professionals (4 family physicians, 2 internal medicine specialists, 1 nurse practitioner, 1 registered nurse, and 1 pharmacist) and 1 nonvoting member (pharmacist project manager) comprised the overarching Lipid Pathway Committee (LPC). Member selection was based on profession, practice setting, and location, and members disclosed any actual or potential conflicts of interest. The guideline process was iterative through online posting, detailed evidence review, and telephone and online meetings. The LPC identified 12 priority questions to be addressed. The Evidence Review Group answered these questions. After review of the answers, key recommendations were derived through consensus of the LPC. The guidelines were drafted, refined, and distributed to a group of clinicians (family physicians, other specialists, pharmacists, nurses, and nurse practitioners) and patients for feedback, then refined again and finalized by the LPC. RECOMMENDATIONS Recommendations are provided on screening and testing, risk assessments, interventions, follow-up, and the role of acetylsalicylic acid in primary prevention. CONCLUSION These simplified lipid guidelines provide practical recommendations for prevention and treatment of CVD for primary care practitioners. All recommendations are intended to assist with, not dictate, decision making in conjunction with patients.

[1]  T. Ivanova,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2016 .

[2]  David R Thompson,et al.  Exercise-based cardiac rehabilitation for coronary heart disease. , 2016, The Cochrane database of systematic reviews.

[3]  G. M. Allan,et al.  Comparison of cardiovascular disease risk calculators , 2014, Current opinion in lipidology.

[4]  T. Wadden,et al.  Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. , 2014, Journal of the American Pharmacists Association : JAPhA.

[5]  Janusz Wnek,et al.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[6]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[7]  G. M. Allan,et al.  Treating to target: ready, fire, aim. , 2014, Canadian family physician Medecin de famille canadien.

[8]  G. M. Allan,et al.  Statin-induced diabetes: too sweet a deal? , 2013, Canadian family physician Medecin de famille canadien.

[9]  G. M. Allan,et al.  Agreement Among Cardiovascular Disease Risk Calculators , 2013, Circulation.

[10]  Simon L Bacon,et al.  The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[11]  Mikael Fogelholm,et al.  Faculty of 1000 evaluation for Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013 .

[12]  Robert Dufour,et al.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. , 2013, The Canadian journal of cardiology.

[13]  M. Taljaard,et al.  Quality of cardiovascular disease care in Ontario, Canada: missed opportunities for prevention - a cross sectional study , 2012, BMC Cardiovascular Disorders.

[14]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[15]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[16]  Lawrence A Leiter,et al.  Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative , 2011, Canadian Medical Association Journal.

[17]  Salomeh Keyhani,et al.  Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study , 2011, BMJ : British Medical Journal.

[18]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[19]  F. Rodríguez-Salvanés,et al.  Impact of comprehensive and intensive treatment of risk factors concerning cardiovascular mortality in secondary prevention: MIRVAS Study. , 2011, Revista espanola de cardiologia.

[20]  D. Lee,et al.  Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. , 2011, Archives of internal medicine.

[21]  D. Mikhailidis,et al.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.

[22]  R. Califf,et al.  Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.

[23]  R. Jackson,et al.  Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? , 2008, Heart.

[24]  F. McAlister,et al.  The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials , 2008, Canadian Medical Association Journal.

[25]  S. Mohiuddin,et al.  Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. , 2007, Chest.

[26]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[27]  Katrina M. Krause,et al.  Is There Time for Management of Patients With Chronic Diseases in Primary Care? , 2005, The Annals of Family Medicine.

[28]  N. Anthonisen,et al.  The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial , 2005 .

[29]  T. Wilt,et al.  Effectiveness of statin therapy in adults with coronary heart disease. , 2004, Archives of internal medicine.

[30]  G. Schuler,et al.  Percutaneous Coronary Angioplasty Compared With Exercise Training in Patients With Stable Coronary Artery Disease: A Randomized Trial , 2004, Circulation.

[31]  Katrina M. Krause,et al.  Primary care: is there enough time for prevention? , 2003, American journal of public health.

[32]  D. Pella,et al.  Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial , 2002, The Lancet.

[33]  P. Touboul,et al.  Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease , 1994, The Lancet.

[34]  G. M. Allan,et al.  Contributors to primary care guidelines: What are their professions and how many of them have conflicts of interest? , 2015, Canadian family physician Medecin de famille canadien.

[35]  Lawrence A Leiter,et al.  The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[36]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .